Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway  by Kung, Andrew L et al.
A R T I C L E
Small molecule blockade of transcriptional coactivation
of the hypoxia-inducible factor pathway
Andrew L. Kung,1,2,* Sonya D. Zabludoff,3,6 Dennis S. France,3 Steven J. Freedman,1,4,7
Elizabeth A. Tanner,1 Annelisa Vieira,1 Susan Cornell-Kennon,3 Jennifer Lee,3 Beqing Wang,3
Jamin Wang,3 Klaus Memmert,5 Hans-Ulrich Naegeli,5 Frank Petersen,5 Michael J. Eck,1
Kenneth W. Bair,3,8 Alexander W. Wood,3 and David M. Livingston1,*
1Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115
2 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Children’s Hospital, Boston, Massachusetts 02115
3 Novartis Pharmaceuticals Corporation, Oncology Department, Cambridge, Massachusetts 02139
4 Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115
5 Novartis Pharma AG Natural Products Unit/Discovery Technologies, Basel, Switzerland CH-4002
6 Present address: AstraZeneca, Cancer Discovery, R & D Boston, Waltham, Massachusetts 02451
7 Present address: Merck Research Laboratories, West Point, Pennsylvania 19486
8 Present address: Chiron Corporation, Emeryville, California 94608
*Correspondence: andrew_kung@dfci.harvard.edu; david_livingston@dfci.harvard.edu
Summary
Homeostasis under hypoxic conditions is maintained through a coordinated transcriptional response mediated by the
hypoxia-inducible factor (HIF) pathway and requires coactivation by the CBP and p300 transcriptional coactivators. Through
a target-based high-throughput screen, we identified chetomin as a disrupter of HIF binding to p300. At a molecular level,
chetomin disrupts the structure of the CH1 domain of p300 and precludes its interaction with HIF, thereby attenuating
hypoxia-inducible transcription. Systemic administration of chetomin inhibited hypoxia-inducible transcription within tu-
mors and inhibited tumor growth. These results demonstrate a therapeutic window for pharmacological attenuation of
HIF activity and further establish the feasibility of disrupting a signal transduction pathway by targeting the function of a
transcriptional coactivator with a small molecule.
Introduction downstream mediators of signal transduction, such as activated
transcription factors or transcriptional complexes.
Hypoxia is an almost universal hallmark of solid tumorsSignal transduction pathways translate extracellular signals and
environmental stimuli into changes in the gene expression pro- (Vaupel et al., 1998; Zhong et al., 1999). Adaptation to hypoxia
is critical for tumor survival and growth and is mediated in largefile of cells. In cancer, many oncogenic changes deregulate
signal transduction pathways (Darnell, 2002). Additionally, sig- part by transcriptional activation of genes that facilitate short-
term adaptive mechanisms (e.g., increased vascular permeabil-nal transduction pathways also play key roles in maintaining
tumor cell homeostasis, for example, adaptation to hypoxia by ity, vasodilatation, glucose transport, switch to anaerobic me-
tabolism), as well as long-term adaptive mechanisms (e.g., angi-induction of hypoxia-inducible factor (HIF) and expression of
vascular endothelial growth factor (VEGF) (Huang and Bunn, ogenesis) (Harris, 2002; Huang and Bunn, 2003; Pugh and
Ratcliffe, 2003; Semenza, 2002). This coordinated homeostatic2003; Pugh and Ratcliffe, 2003; Semenza, 2002). Efforts to tar-
get key components of signal transduction pathways have re- response is mediated in large part through the activation of
the heterodimeric transcription factor hypoxia-inducible factorsulted in therapeutic successes, most often through inhibition
of receptors or upstream signal mediators. For example, tras- 1 (HIF-1). Tumor hypoxia and overexpression of HIF-1 have
been associated with resistance to certain therapies, increasedtuzumab, imatinib mesylate, and rituximab, exemplars of the
modern paradigm of targeted therapies, all target cell surface risk of invasion and metastasis, and poor outcome in certain
malignancies (Hockel and Vaupel, 2001).receptors. There are few examples of success in targeting
S I G N I F I C A N C E
Adaptation to hypoxia is critical for tumor growth. In this report, we describe our efforts to find a small molecule capable of disrupting
the HIF pathway by blocking the interaction of HIF with its transcriptional coactivator, p300. Although the interaction surface between
these two proteins is extensive, we identify a small molecule that abrogates binding by disrupting the structure of one of the
binding partners. These results demonstrate the feasibility of nonallosteric small molecule perturbation of high-affinity protein-protein
interactions. Furthermore, they show that signal transduction pathways can be attenuated by impinging upon downstream pathway
constituents, such as the function of a transcriptional coactivator. This strategy may be relevant to other signal transduction pathways
aberrantly activated in cancer.
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A number of strategies to preferentially target hypoxic tumor
cells have been devised. The first to achieve clinical utility has
been the development of drugs that have heightened toxicity
under hypoxic conditions, for example, tirapazamine, a hypoxia-
activated topoisomerase II inhibitor (von Pawel et al., 2000).
Experimental approaches include gene therapy constructs con-
taining HREs that drive expression under hypoxic conditions
and prodrug activation by obligate anaerobic microbes (Brown,
2002). Additionally, recent reports have identified inhibition of
the HIF pathway by antimicrotubule agents (Mabjeesh et al.,
2003), topoisomerase inhibitors (Rapisarda et al., 2002), histone
deacetylase inhibitors (Mie Lee et al., 2003), and HSP90 inhibi-
tors (Hur et al., 2002; Isaacs et al., 2002; Mabjeesh et al., 2002),
although the specificity of these effects and relevance vis-a`-vis
their antitumor activities in vivo is not clear.
We and others have previously shown that p300 and CBP
are critical coactivators of the HIF-1 pathway (Arany et al., 1996;
Carrero et al., 2000; Ema et al., 1999; Kung et al., 2000). Dis-
rupting the normal interaction of p300/CBP with HIF-1 by ret-
roviral overexpression of a blocking polypeptide resulted in di-
Figure 1. HTS for disrupters of HIF-1/p300 binding minished hypoxia-inducible transcription and decreased tumor
A: Schematic of HIF-1 hypoxia response pathway. growth in xenograft models (Kung et al., 2000). While these
B: Time-resolved fluorescence HTS for inhibitors of HIF-p300 binding. Biotinyl- approaches provide experimental support for the importance
ated HIF-1 polypeptide (TADC) was immobilized on streptavidin plates. In of the HIF pathway in tumorigenesis, therapeutic delivery ofthe presence of compounds, the binding of bacterially produced GST-CH1
moderate-sized blocking polypeptides is not readily feasible.was probed with a europium (Eu)-conjugated anti-GST antibody.
C: Structure of chetomin. Although pharmacological manipulation of nuclear protein-pro-
tein interactions has proven difficult (Cochran, 2000), there have
been a limited number of recent successes (Berg et al., 2002;
Lepourcelet et al., 2004). Here, we describe a target-based
Many of the mechanisms that regulate the HIF-1 pathway screen that identified a small molecule inhibitor of the interaction
have been recently elucidated (Figure 1A). Under conditions of of HIF-1 with p300. We demonstrate that the small molecule
normal oxygenation, the regulated -subunit (HIF-1) is hydrox- attenuates hypoxia-inducible transcription in cell culture, as well
ylated on prolines 402 and 564 in oxygen-dependent reactions, as within tumor xenografts, and has antitumor efficacy in vivo.
targeting HIF-1 to the von Hippel-Lindau (vHL) ubiquitination
complex and ultimate degradation by the proteasome system Results
(Huang et al., 1998; Ivan et al., 2001; Jaakkola et al., 2001;
Kallio et al., 1999; Masson et al., 2001). In this manner, HIF-1 High-throughput screen for disrupters
abundance is maintained at nominal levels under normoxic con- of HIF-1/p300 binding
ditions. As oxygen becomes rate limiting, proline hydroxylation We developed a high-throughput screen (HTS) to search for
diminishes, and HIF-1 accumulates and heterodimerizes with small molecules capable of disrupting the interaction of HIF-1
the constitutively present -subunit (HIF-1, aryl hydrocarbon with p300 (Figure 1B). A biotinylated, 41 amino acid polypeptide
nuclear translocator) (Huang and Bunn, 2003; Pugh and Rat- corresponding to the minimal p300/CBP binding domain of HIF-
cliffe, 2003). A third site of regulatory hydroxylation on aspara- 1 (TADC; residues 786-826 [Kung et al., 2000]) was synthesized
gine 803 is also inhibited under hypoxic conditions, allowing and immobilized on streptavidin-coated multiwell plates. The
for recruitment of the p300 and CREB binding protein (CBP) minimal HIF-1 binding domain of p300 (CH1; residues 302-
transcriptional coactivators (Lando et al., 2002). Binding of this 423 [Kung et al., 2000]) was produced in bacteria as a fusion
complex to the cognate hypoxia-response element (HRE) re- to glutathione-S-transferase (GST-CH1). Binding of GST-CH1
sults in transactivation of genes containing such elements within to immobilized TADC, in the presence or absence of com-
promoter or enhancer elements (Semenza, 2002). pounds, was probed by europium-conjugated anti-GST anti-
The near universality of hypoxia in human tumors and cen- body and detected by time-resolved fluorescence. The opti-
mized HTS assay had an average signal-to-noise ratio of greatertrality of the HIF pathway in adapting to hypoxia suggests that
inhibition of the HIF pathway may have therapeutic utility as an than 5:1 and a very robust assay quality parameter Z factor
value (Zhang et al., 1999) of 0.82.antitumor strategy. Inhibition of HIF function in tumors may
attenuate angiogenesis and may contribute directly to tumor A natural and synthetic compound library of 600,000 sub-
stances was subjected to this HTS. Compounds with 50%cell death through metabolic derangement. While some experi-
mental xenograft studies support targeting the HIF pathway as inhibitory activity were titrated to determine a dose-response
relationship (7 point IC50). Due to the high binding affinity ofan antitumor strategy (Kondo et al., 2002; Kung et al., 2000),
other mouse genetic experiments have had conflicting results these polypeptides (Freedman et al., 2002, 2003), the hit rate
was low. There were only 187 titrated hits (0.03% titrated hit(Carmeliet et al., 1998; Hopfl et al., 2002; Ryan et al., 1998,
2000), thus necessitating caution as this strategy is translated rate), which were then subjected to secondary assays consisting
of an in vitro interaction assay of full-length HIF-1 with GST-to clinical utility.
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The molecular formula of the compound was determined by
high-resolution mass spectroscopy (ESI; 9.4 Tesla FT/MS) to
be C31H30N6O6S4 (observed m/z [MH] 711.1182; calculated
m/z 711.1182; rel. error  0.1 ppm; data not shown). NMR
spectroscopy (CDCl3; 500 MHz; tetramethylsilane as internal
standard) revealed that all 1H and 13C shifts (Supplemental Figure
S1 at http://www.cancercell.org/cgi/content/full/6/1/33/
DC1) corresponded with those published for chetomin (Fujimoto
et al., 2004; McInnes et al., 1976). The optical rotation []D23
was 283.2 (c  0.101 in chloroform; data not shown), which
was likewise consistent with the published data of chetomin
(Fujimoto et al., 2004), confirming the absolute stereochemistry
as indicated (Figure 1C). The final purity of chetomin used for
these studies was 98% by HPLC analysis.
Chetomin disrupts HIF-1 and HIF-2 binding to p300
The structural elements that are required for HIF-1 binding to
p300 are largely identical in HIF-2 (Freedman et al., 2002). We
evaluated the ability of chetomin to disrupt binding of HIF-1
and HIF-2 to p300 in an in vitro interaction assay. Full-length
in vitro-translated HIF-1 and HIF-2 bound efficiently to GST-
CH1 (Figure 2A). Addition of chetomin disrupted binding of both
HIF-1 and HIF-2 at similar concentrations.
In cell culture, the interaction of the TADC domain of HIF-1
with the CH1 domain of p300 was evaluated using a mammalian
two-hybrid assay. Here, the interaction of CH1 (p300 aa 311-
528) fused to the VP16 activation domain (VP16-CH1) and the
TADC domain of HIF-1 (aa 776-826) fused to the Gal4 DNA
binding domain (Gal4-TADC) was measured in Hep3B cells.
The hypoxia-induced interaction between TADC and CH1 was
attenuated in a dose-dependent manner by chetomin over a low
nanomolar range (Figure 2B). Prior studies have demonstrated a
Figure 2. Chetomin disrupts HIF-1 and HIF-2 binding to p300
critical requirement for Cys800 within the TADC domain for
A: In vitro interaction assay. Full-length IVT HIF-1 and HIF-2 were bound binding to p300 (Ema et al., 1999; Gu et al., 2001). Covalentto GST-CH1 in the absence or presence of chetomin at the indicated con-
attack of Cys800 in TADC by chetomin was excluded as acentrations or to GST as a negative control.
possible mechanism of action, since chetomin was equally effi-B: Mammalian two-hybrid interaction assay. Hep3B cells were cotrans-
fected with VP16-CH1 and the indicated Gal4-fusion of HIF-1 (G4-HIF), an cacious against a Cys800Val mutant of TADC (Figure 2B) that
interacting mutant (G4-HIF-C800V), or a noninteracting mutant (G4-HIF- has been previously reported to bind CH1 with heightened affin-
C800S). Relative two-hybrid interaction was determined under normoxic
ity (Gu et al., 2001). There were significant differences in cheto-or hypoxic conditions and in the absence or presence of the indicated
min doses required to disrupt HIF-1/CH1 interaction in vitroconcentrations of chetomin. Reporter activity is normalized to an internal
transcriptional control (-galactosidase activity) and expressed as the aver- (Figure 2A) compared to in cells (Figure 2B), which we attribute
age of triplicates 	 SD. to the microgram quantities of GST-CH1 used in the in vitro
C: Interaction of endogenous HIF-1 and p300. HepG2 cells were treated interaction assays, in comparison to normal intracellular con-with 50 nM chetomin (CTM) or solvent (DMSO) under normoxic or hypoxic
centrations of the relevant proteins.conditions. HIF-1 was immunoprecipitated (IP HIF-1) from normalized ali-
To determine if chetomin disrupted the interaction of endog-quots of nuclear extract, and HIF-1 and p300 were detected by immu-
noblot. Cellular abundance of p300 was determined by immunoblot of 50 enous HIF-1 with p300, endogenous HIF-1 was immunopre-

g of unfractionated nuclear extract (NE). cipitated from cells, and coimmunoprecipitated p300 was de-
tected by immunoblot. As expected, under normoxic conditions
the abundance of HIF-1 is nominal (Figure 2C). Under hypoxic
conditions, HIF-1 is readily detectable and exists in complexCH1 (see Figure 2A) and a cell-based assay utilizing the hypoxia-
with p300. While chetomin had no appreciable effect on abun-responsive erythropoietin (EPO) enhancer driving luciferase (see
dance of HIF-1 or p300 under hypoxic conditions, the abun-Figure 4A). From this HTS and secondary analyses, a single
dance of p300 complexed with HIF-1was significantly reducedsubmicromolar inhibitor or HIF-1/p300 interaction, chetomin
upon treatment with chetomin (Figure 2C). Thus, chetomin dis-(Figure 1C), was identified.
rupts p300/HIF-1 protein-protein interaction in vitro and withinChetomin, a dithiodiketopiperazine metabolite of the fungus
cells.Chaetomium species, has been previously characterized as hav-
ing antimicrobial activity (Brewer et al., 1972; Sekita et al., 1981).
Chetomin disrupts CH1 structure/functionComplete synthesis of chetomin has not been achieved, and
To test whether chetomin globally disrupts p300 function, weas such the compound used for subsequent studies was pro-
evaluated the transcriptional activity of proteins binding to vari-duced by fermentation, followed by organic extraction, and puri-
fication by silica gel and reverse phase C18 chromatography. ous domains of p300. The p300 binding domain of each protein
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are not protected from solvent exposure by the structural fold,
exchangeable amide protons are rapidly replaced by deuterium
ions, which do not have a NMR signal. Lower concentrations
of chetomin delayed the onset of change and/or produced only
a partial effect, and solvent alone (DMSO) had no effect on the
NMR spectrum. Spectral changes observed with chetomin were
similar to those caused by EDTA-mediated chelation of zinc
ions coordinated by CH1 (Figure 3B), which is known to disrupt
its structure (Freedman et al., 2002). Mass spectroscopy dem-
onstrated that chetomin does not covalently modify the CH1
domain or the HIF-1 peptide (data not shown). Taken together,
these findings indicate that chetomin targets the CH1 domain
of p300, disrupting its global fold and thereby preventing inter-
action with HIF-1, as well as other CH1-interacting proteins.
Chetomin attenuates hypoxia-inducible transcription
Having determined that chetomin disrupts binding of HIF to
p300, we wanted to determine if chetomin attenuated hypoxia-
inducible transcription. Utilizing three hypoxia-responsive re-
porters in cell-based assays, chetomin was found to attenuate
hypoxia-induced reporter activity at low nanomolar concentra-
tions (Figure 4A). All luciferase values were normalized to the
CMV-driven expression of -galactosidase as an internal con-
Figure 3. Chetomin disrupts the structure and function of CH1 trol. At the indicated concentrations, there was no significant
A: Transactivation of p300-interacting proteins. The DNA binding domain of alteration of CMV promoter-driven luciferase activity (Figure 4A),
Gal4 was fused to the p300 binding domain of the indicated proteins. The which indicates that chetomin was not directly perturbing theeffect of chetomin on p300-mediated transcription is expressed as luciferase
activity of luciferase. These effects were also not due to nonspe-activity normalized to an internal control for transcription. Where indicated,
cells were exposed to hypoxia. cific transcriptional repression or cytotoxicity, since standard-
B: Effect of chetomin on CH1 structure. One-dimensional proton NMR spec- ization to an internal control would correct for decreased overall
tra in the absence (CH1) or presence of solvent alone (DMSO), chetomin, cell numbers. Furthermore, there was no appreciable decrease
or EDTA. Only the upfield alipathic region is shown.
in cell viability in HCT116, Hep3B, or human umbilical vein endo-
thelial cells when grown in chetomin up to concentrations of
250 nM for 24 hr (data not shown).
To further verify effects on hypoxia-inducible transcription,was fused to the Gal4 DNA binding domain. p300-dependent
real-time RT-PCR was used to quantify the abundance of atranscriptional activity was assayed as activity from a Gal4-
panel of hypoxia-induced transcripts. Here too, chetomin re-luciferase reporter. Chetomin had no significant effect on RAR,
duced the abundance of multiple hypoxia-induced transcripts,SREBP2, or SRC-1 transcriptional activity (Figure 3A), demon-
albeit with varying efficacy (Figure 4B).strating that chetomin did not globally inhibit p300 activity, as
VEGF is a primary mediator of vascular permeability andthese factors bind to the amino-terminal, KIX, and glutamine-
angiogenesis, and its production is induced by hypoxia (Figuresrich domains, respectively. STAT2 transcriptional activity, how-
4C and 4D). Cellular abundance (Figure 4C) as well as superna-ever, was significantly attenuated by chetomin, in a manner
tant levels of secreted VEGF (Figure 4D) protein were both atten-parallel to HIF-1. Since STAT2 also binds to the CH1 domain
uated by addition of chetomin in a dose-dependent manner.(Bhattacharya et al., 1996), these data suggest that chetomin
Taken together, these results demonstrate that chetomin atten-disrupts CH1 function but not p300 function in entirety. These
uates hypoxia-inducible gene expression in cell culture and isresults also demonstrate that chetomin is not a nonspecific
not a global inhibitor of transcription at the concentrations thattranscriptional inhibitor.
were used in these studies.To more directly probe the effect of chetomin on CH1, we
used NMR spectroscopy to determine the effect of chetomin
Chetomin attenuates HIF pathway function in vivoon the structure of CH1 (Figure 3B). Addition of a 2-fold molar
When chetomin was administered intravenously in mice,excess of chetomin to HIF-1 in complex with CH1 did not alter
2 mg/kg was the maximally tolerated single dose. Pharmacoki-the 1D proton NMR spectrum (data not shown). In contrast, the
netic analysis revealed variable peak plasma levels of 1375 	same amount of chetomin added to the CH1 domain alone
1020 nM that were achieved immediately after injection, withcaused a loss of proton peak dispersion (i.e., the range over
an elimination half-life of 4 hr. Peak xenograft tumor levels werewhich peaks are present) and broadening of spectral linewidths
achieved 4 hr after a single intravenous dose, with peak tumor(i.e., the widths of the peaks that are present). These changes
concentration of 300 nM (data not shown).indicate that CH1 becomes less structured in the presence of
To determine if chetomin affected HIF-1 pathway in vivo,chetomin because spectral complexity is reduced when amino
we first determined the effect of chetomin on serum EPO levels,acids become exposed to a uniform solute environment. This
as a biomarker of physiological HIF-1 function (Semenza, 2002).is further supported by the chetomin-induced disappearance
Mice were treated either with three daily doses of chetomin atof amide proton peaks (i.e., centered around 8.35 ppm; data
not shown) in a D2O-containing solvent. Here, when amino acids 2 mg/kg i.v. or with vehicle control. Serum was collected 6 hr
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Figure 4. Chetomin attenuates hypoxia-induc-
ible transcription
A: Hypoxia-inducible reporter assays. Hep3B
cells were transfected with the indicated hyp-
oxia-responsive reporters (3xHRE-Luc, EPO-Luc,
VEGF-Luc) or a constitutive control (CMV-Luc).
Reporter activity under normoxic or hypoxic con-
ditions and in the absence or presence of the
indicated concentrations of chetomin (CTM) are
expressed normalized to an internal control for
transcription (-galactosidase activity).
B: Abundance of hypoxia-inducible mRNA. The
abundance of the indicated hypoxia-responsive
transcripts under normoxic (open bars) or hyp-
oxia-mimetic conditions (deferoxamine [DFO];
filled bars) was quantified by real-time RT-PCR.
The effect of chetomin is expressed as the aver-
age of triplicate experiments 	 SD.
C and D: Cellular and secreted VEGF abun-
dance. Hep3B cells treated in the absence or
presence of chetomin (CTM) and hypoxia or
DFO were lysed and immunoblotted for VEGF
(C), or the abundance of VEGF in the tissue cul-
ture supernatant was assayed by ELISA (D).
after the final dose, and EPO was immunoprecipitated and then clearly visualized 48 hr after implantation (Figure 6A). Specificity
of the reporter activity was validated by the fact that lumines-quantified by immunoblot. Animals that were treated acutely
with chetomin had a significant decrement in serum EPO levels cence was attenuated by concomitant expression of dnHIF
polypeptide and superactivated by HIF-VP16, a constitutively(Figure 6A). Consistent with these acute effects, animals that
were treated for 3 weeks with chetomin (see Figure 7A) had active allele of HIF-1. The retroviral vector controls (pMMP
and pBP) were comparable to otherwise unmodified reporterspecific decreases in red blood cell counts (Figure 6B).
The effect of acute administration of chetomin on pathologi- cells (Figure 6A). Thus, the luminescent signal emanating from
these reporter cells was a reflection of the transcriptional activitycal HIF-1 activity was evaluated in mice bearing established
HCT116 xenograft tumors. Mice were again treated with either of the HIF-1 pathway within these tumors.
To assess the in vivo effect of chetomin on hypoxia-induciblethree daily doses of chetomin at 2 mg/kg i.v. or vehicle control.
We evaluated the effect of chetomin on the expression of two transcription, we innoculated nude mice with hypoxia reporter
cell line on the right flank (HepG2-EPO-Luc). As an internalHIF-1 target genes, glucose transporter 1 (Glut1) and VEGF, by
immunohistochemistry and ELISA, respectively. Since oxygen- control, a cell line with luciferase constitutively expressed from
the CMV promoter was implanted on the left flank (HepG2-ation within tumors is highly heterogeneous, we examined Glut
1 immunoreactivity specifically in perinecrotic areas, where cells CMV-Luc). Mice were imaged 48 hr after implantation to estab-
lish baseline reporter activity and were then i.v. injected withare most hypoxic and there is peak hypoxia-driven gene expres-
sion (Damert et al., 1997). VEGF levels were determined from either 2 mg/kg chetomin or vehicle control. After two doses, 24
hr after baseline imaging, mice were reimaged (Figure 6B). Totalstandardized tumor lysates. Chetomin was found to acutely
attenuate both Glut1 expression (Figure 5C) and tumor VEGF flux of photons through a standardized region of interest drawn
around each injection site was determined, and hypoxia-specificlevels (Figure 5D), as biomarkers of HIF-1 activity within tumors.
To directly determine the effect of chetomin on the HIF-1 reporter activity was derived as the ratio of luminescence from
EPO-Luc-containing cells relative to the constitutive internalpathway within tumors, we used in vivo bioluminescence im-
aging to quantify hypoxia-inducible transcription. We created a control (EPO-Luc/CMV-Luc). Hypoxia-specific reporter activity
was marginally increased in vehicle-treated mice (11%,hypoxia reporter cell line in which luciferase was expressed
under control of the EPO enhancer (HepG2-EPO-Luc). In cell 13%) over the treatment period. In contrast, the hypoxia re-
porter activity in mice treated with chetomin was reduced byculture, this reporter cell line had100-fold induction of reporter
activity under hypoxic conditions when compared to normoxic approximately half (40%,52%). These results, together with
the biomarker studies above, demonstrate that systemic admin-conditions (data not shown). To validate the cell line for in vivo
istration of chetomin attenuates both physiological and patho-assessment of hypoxia-induced transcription, aliquots of the
logical HIF-mediated gene expression.reporter cell line were infected with retroviruses encoding domi-
nant-negative (dnHIF) or dominant-positive (HIF-VP16) media-
tors of HIF-mediated transcription, as previously described In vivo disruption of HIF/p300 interaction
We adapted a previously described method for molecular im-(Kung et al., 2000). When identical numbers of cells were im-
planted as xenografts in nude mice, bioluminescence was aging of protein-protein interactions (Ray et al., 2002) to evaluate
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Figure 5. Chetomin attenuates HIF-1 biomarkers
in vivo
A: Serum EPO levels in mice treated with 2 mg/kg
of chetomin or vehicle control via tail vein, daily
for 3 days. Data presented relative to control
levels; mean 	 SEM; n  4 in each group; *p 
0.05.
B: Blood counts from individual mice treated 3
weeks with chetomin (red squares) or vehicle
control (blue diamonds). See Figure 7A for dosing
regimen. Normal range of lab values indicated
by gray shading.
C and D: Glut1 immunostaining (C) and VEGF
levels (D) in HCT116 xenograft tumors treated
with three daily doses of chetomin at 2 mg/kg
or vehicle control. For Glut1 immunostaining
(brown), representative areas with comparable
localization relative to areas of necrosis (Necr)
are shown. VEGF levels are reported as pg of
human VEGF per mg of tumor lysate.
the effect of chetomin on the interaction of HIF-1 with p300. As weeks), followed by a limited number of tail vein injections (1
week). In comparison to mice treated with vehicle control,with the cell culture mammalian two-hybrid assays described
in Figure 2B, reporter cells were created by cotransfecting plas- 2 mg/kg of chetomin given at the indicated frequency had sig-
nificant antitumor activity (Figure 7A) without significant effectsmids expressing Gal4-TADC and VP16-CH1. The activity of
luciferase expressed from a Gal4-Luciferase vector was used on body weight over the treatment period (Figure 7B). Necropsy
revealed coagulative necrosis at sites of tail vein injection (dataas a quantitative measure of this protein-protein interaction (Ray
et al., 2002). Control cells were created by expressing the Gal4 not shown), and blood counts revealed anemia and leukocytosis
(Figure 5B). We have not been able to determine the cause ofDNA binding domain fused directly to VP16 (Gal4-VP16) to con-
stitutively drive expression of Gal4-Luc. the local coagulative necrosis and leukocytosis but suspect that
the latter may be a secondary effect of the former. There wasWe inoculated mice with two-hybrid reporter cells in the
right flank and constitutive control cells in the left flank (Figure no other overt end-organ toxicity in chetomin-treated mice.
When given at a lower dose of 1 mg/kg, the onset of local6C). After 24 hr, mice were imaged to determine baseline re-
porter activity. Animals were then treated with either chetomin toxicity at sites of injection was significantly diminished. When
chetomin was administered daily at 1 mg/kg i.v., there was(2 mg/kg) i.v. or vehicle control. After three daily doses, mice
were reimaged (Figure 6C). In all cases, two-hybrid interaction likewise significant antitumor efficacy in mice xenografted with
PC3 cells (Figure 7C). Histological examination of tumor sec-reporter luminescence was normalized to the control lumines-
cence on the contralateral flank (i.e., to correct for cytotoxic or tions revealed significant necrosis in chetomin-treated tumors
in comparison to minimal necrosis in vehicle-treated mice atnonspecific effects), and results are expressed relative to the
baseline activity. With this molecular imaging approach, cheto- comparable distances from the tumor surface (Figure 7D). Im-
munostaining for HIF-induced gene products (e.g., Glut1, VEGF)min was found to significantly disrupt the TADC/CH1 protein-
protein interaction within tumors in vivo (Figure 6D), as it did and vasculature revealed vast regional variability in chetomin-
treated tumors and were uninterpretable as to whether theyin vitro (Figure 2A) and in cell culture (Figures 2B and 2C).
were primary or late downstream treatment effects.
Effects of chetomin on tumor growth
We utilized xenograft tumor models to evaluate the effect of Discussion
chetomin on tumor growth. HCT116 colon cancer cells were
implanted subcutaneously and allowed to grow to approxi- Disrupting the ability of tumors to adapt to hypoxia may be an
attractive antitumor strategy given the universality of hypoxiamately 50 mm3 prior to initiation of therapy. When given at 2
mg/kg, chetomin was found to cause local toxicity at sites of in solid tumors. Our prior studies demonstrated that attenuation
of the HIF-1 pathway could be achieved through blockade ofrepeated intravenous injection, and this limited the number of
doses that could be administered by tail vein injection. As such, the interaction of p300/CBP with HIF-1 through the overex-
pression of a blocking polypeptide in tumor cells (Kung et al.,treatments were administered by injection through a central
venous catheter for the effective lifespan of such catheters (2 2000). Here, we describe our efforts to find a small molecule
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Figure 6. Chetomin disrupts HIF pathway activity in vivo
A: In vivo imaging of HIF-1 activity. HepG2 cells with stably integrated EPO-Luc reporter were implanted without further modification or after infection with
retroviruses encoding a dominant-negative HIF polypeptide (pMMP-dnHIF), dominant-positive HIF-1 allele (pBP-HIF-VP16), or controls for retroviral infection
(pMMP, pBP). Mice were imaged 48 hr after implantation of cells.
B: In vivo effects of chetomin. Hypoxia reporter cells (EPO-Luc) were implanted on the right flank, and constitutive control cells (CMV-Luc) were implanted
on the left flanks of mice. Animals were imaged prior to (Pre-Rx) and after (Post-Rx) i.v. administration of two doses of chetomin (2 mg/kg) or vehicle control.
HIF-1-specific activity was determined by calculating the ratio of EPO-Luc/CMV-Luc.
C: In vivo imaging of TADC-CH1 protein-protein interaction. Mice were inoculated with two-hybrid reporter cells in the right flank and constitutive control
cells in the left flank. After baseline imaging, mice were treated with two doses of chetomin (2 mg/kg) or vehicle control, followed by reimaging 24 hr after
initial imaging.
D: For each animal, TADC-CH1 two-hybrid interaction (right flank) was normalized to the constitutive control (left flank) and expressed relative to the
baseline ratio for each animal; mean 	 SEM; n  4; *p  0.05.
capable of blocking this nuclear protein-protein interaction. The by stromal elements (Fukumura et al., 1998), and furthermore,
attenuation of HIF may also have direct effects on endothelialprimary candidate that emerged from a target-based HTS, chet-
omin, was found to indeed be able to block the interaction of cell viability or function as suggested by recent studies (Sowter
et al., 2003; Yamakawa et al., 2003). It is thus possible that,HIF-1 and HIF-2 with p300 by disrupting the HIF-interacting
domain of p300. This resulted in attenuation of hypoxia-induc- since HIF-VP16 is expressed solely in the tumor cells, partial
rescue results from the unimpeded effects of chetomin on hostible transcription in cell culture, as well as in vivo when systemi-
cally administered in mice. elements. Although the precise function and requirement for
the HIF pathway in the tumor and host compartments are activeWhile the biomarker analyses (EPO/VEGF/Glut1 levels,
in vivo molecular imaging) suggest that chetomin indeed hits areas of study, the current results with chetomin suggest a
therapeutic window for inhibition of HIF function as a therapeuticits intended target, the HIF pathway and specifically HIF-p300
interaction, in vivo, the exact basis of the downstream antitumor target.
We demonstrate that the HIF-1 pathway can be attenuatedactivity requires further investigation. Our attempts to rescue
tumors from chetomin by overexpressing HIF-VP16 in tumor by blocking the function of an associated transcriptional coacti-
vator. This approach does not confer absolute specificity ofcells, as we have previously done (Kung et al., 2000), resulted
in only partial rescue of tumor growth (data not shown). One action, and our results suggest that other CH1-interacting tran-
scriptional pathways are also blocked. Indeed, another possiblepossible explanation for this finding is that systemically adminis-
tered inhibitors target both tumor and host elements (e.g., stro- explanation for partial rescue of tumor growth with HIF-VP16
(see above) is that chetomin may have off-target effects thatmal cells, endothelial cells). The importance of the stroma in
supporting tumor growth is underscored by the fact that a large contribute to antitumor efficacy. However, in our prior studies
utilizing a polypeptide to block CH1, the in vivo antitumor effectsfraction of VEGF within mouse tumors is actually produced
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Figure 7. Chetomin attenuates tumor growth
in vivo
A and B: Chetomin effects on (A) tumor growth
and (B) body weight in mice with HCT116 xeno-
grafts. Animals with established tumors after 1
week of growth were divided into groups treated
with 2 mg/kg chetomin i.v. or vehicle control
(arrows indicate doses). Data represent means	
SEM; n  6 per group; *p  0.05; **p  0.005. NS,
not significant.
C: Effects of chetomin (1 mg/kg) i.v. daily (5
days/week) or vehicle control on growth of es-
tablished PC3 xenografts. Data presented as
mean 	 SEM; n  10 per group; *p  0.05.
D: Low-power view of H&E-stained tumor sec-
tions from PC3 xenografts. The tumor surfaces
and areas of necrosis are indicated. The scale is
identical in the two panels.
were largely attributable to inhibition of the HIF pathway, since Modern drug discovery is increasingly focused on targeting
pathognomonic changes in cancer cells. There are broadoverexpressing HIF-VP16 largely rescued tumor growth (Kung
et al., 2000). Our results also demonstrate that chetomin is classes of targets, however, where selectivity may not result
from absolute restriction in expression but rather from differen-also not totally nonspecific. That is, cellular transcription is not
globally attenuated, as it is with actinomycin D, nor is the func- tial function in tumor cells in comparison to their normal counter-
parts. Recent clinical success with bortezomib, an inhibitor oftion of p300/CBP lost in entirety. Since p300 and CBP are
critical coactivators of many transcriptional pathways that are proteosome function, is one such example. The HIF pathway
ectopically activated in cancer, this strategy may have broader is another example, in that the pathway is present in all cells,
utility in targeting other transcriptional pathways and transcrip- but hypoxic tumors may have a heightened dependence upon
tion factors. Attacking downstream mediators of transcription its function for survival and growth. While further development
has the theoretical advantage of targeting common end ef- of chetomin as a therapeutic may be limited by its local toxicity,
fectors in the case of pathways where mutations in multiple the results presented herein suggest that the HIF pathway can
upstream components could all contribute to ectopic activation, be attenuated in vivo with a therapeutic window. Additional
e.g., the WNT pathway (Morin et al., 1997). Recent reports of target-based screens derived from our expanding knowledge
peptidic (Lau et al., 2000) and small molecule inhibitors (Balasu- of the molecular regulation of the HIF pathway or phenotypic
bramanyam et al., 2003) of p300/CBP acetyltransferase activity cell-based screens utilizing hypoxia reporter cells (Rapisarda et
suggest another method for attacking these coactivators. al., 2002), will hopefully yield additional candidate compounds
There are only a few examples where a signal transduction for development and evaluation as potential clinical thera-
pathway has been disrupted by small molecule inhibition of a peutics.
downstream protein-protein interaction (Berg et al., 2002; Le-
Experimental procedurespourcelet et al., 2004). The interaction surface of p300/CBP
with HIF-1 is extensive, totaling 3393 A˚, and the a priori predic-
Reagents, plasmids, and retrovirusestion would be that it would be difficult to find a small molecule
Except where otherwise noted, all reagents were from Sigma. Mammalian
capable of blocking this extended protein-protein interaction two-hybrid vectors pB42-CH1, pGal4-CAD, pGal4-CAD-C800V, and pGal4-
(Freedman et al., 2002). The mechanism of action in the case CAD-C800S were kind gifts of L. Eric Huang (National Cancer Institute) (Gu
of chetomin appears to be disruption of the tertiary structure et al., 2001). pcDNA3-HA-HIF-2 was kindly provided by William G. Kaelin,
Jr. (Dana-Farber Cancer Institute). All other plasmids and retroviruses haveof CH1. This result suggests that blockade of protein-protein
been previously described (Bhattacharya et al., 1999; Kung et al., 2000).interactions may not require physical allosteric blockade of bind-
ing but rather may be accomplished through induction of struc-
Fermentation and isolation of chetomin
tural changes of one of the binding partners. The inverse has
Chetomin was produced by fermentation of Chaetomium sp., followed by
previously been demonstrated, in which protein structure and extraction and purification by column chromatography. Details are provided
function has been restored by small molecule modulation of in the Supplemental Data at http://www.cancercell.org/cgi/content/full/6/1/
33/DC1.mutant p53 structure (Foster et al., 1999).
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HIF-1/p300 HTS formed with 2.5 
g of total RNA added to buffer, random hexamers, dNTPs,
RNase inhibitor, and reverse transcriptase (TaqMan; Applied Biosystems)GST-CH1 was expressed in BL21 pLysS cells (Promega), transformed with
pGEX-2T-CH1 (aa 302-423) (Kung et al., 2000), and grown in Luria-Bertani according to the manufacturer’s instructions. Real-time PCR was then con-
ducted using 5 
l of template according to the manufacturer’s instructionsbroth media supplemented with 0.1 mM ZnCl2. Expression was induced with
0.4 mM IPTG overnight at 25C. The bacteria were lysed by sonication in (SYBR Green PCR; Applied Biosystems). Reactions were run and analyzed
using the 5700 GeneAmp instrument and software (Applied Biosystems).lysis buffer (50 mM Tris 8.0, 150 mM NaCl, 100 
M ZnCl2, 1 mM EDTA, 10
mM MgCl2, 1 mM dithiothreitol (DTT), 0.1% NP40, 50 
g/ml RNAase A, 50

g/ml DNAase, 10 
M pepstatin, 10 
M leupeptin, and 1 mM Pefabloc Immunoblot and ELISA analysis of VEGF
[Roche]). After centrifugation, GST-CH1 fusion protein was purified by Gluta- Hep3B cells were treated with compound or vehicle control (DMSO) for 8 hr
thione-Sepharose 4B (Amersham) column chromatography according to the prior to addition of 125 
M DFO to induce hypoxia response. After 18 hr,
manufacturer’s instructions. After elution with 50 mM glutathione, fractions cells were lysed in 100 mM Tris-Cl 6.8, 4% SDS, 20% glycerol, and protease
with highest protein concentration were pooled and dialyzed overnight at inhibitor cocktail. After centrifugation, the protein concentration of the super-
4C in 2 liters of 50 mM Tris 8.0, 150 mM NaCl, 100 
M ZnCl2, 1 mM DTT, natant was determined (BioRad), and 50 
g of each lysate was resolved
0.1% NP40, 10% glycerol, and 0.1 mM Pefabloc. The GST-CH1 protein by SDS-PAGE on a 12% Tris-glycine gel. After transfer to nitrocellulose,
was filtered and stored at 70C. immunodetection with anti-VEGF antibody (AB1442; Chemicon) was per-
Multiwell plates (Nunc) were coated with streptavidin 1 
g/ml overnight formed using standard techniques. Tissue culture supernatant levels of VEGF
at 4C in PBS. The plates were washed with 50 mM Tris 8.0, 150 mM was determined using a VEGF immunoassay (R&D Systems) according to
NaCl, and 0.05% Tween 20 (TBST). Synthetic N-terminal biotinylated HIF- the manufacturer’s instructions.
1 peptide (aa 786-826) was bound in 50 mM Tris 8.0, 150 mM sodium
chloride, and 5% bovine serum albumin (assay buffer) for 2 hr at 4C. The In vivo EPO and VEGF levels, Glut1 immunostain,
plates were washed with TBST, and 111 pM GST-CH1 was added to the and blood counts
plates in assay buffer with 0.1% Tween 20, 0.5 mM DTT, and 10 
M ZnCl2 NCr/Nude mice (Taconic) either with or without HCT116 xenografts were
and in the presence or absence of compounds for 2 hr at 4C. The assay treated for the indicated periods of time with chetomin or vehicle control
plates were washed with TBST, and europium-labeled anti-GST antibody (10% DMSO, 4.5% dextrose). After humane euthanasia, blood was immedi-
was added in assay buffer with 10 
M ZnCl2 and incubated overnight at ately collected by intracardiac aspiration. For EPO levels, serum was isolated
4C. The plates were washed with TBST, DELFIA enhancement solution using a serum separator tube (BDBioscience). Serum EPO was immunopre-
(Wallac) was added, and fluorescence was read on a Victor I time-resolved cipitated from 200 
l of serum using a polyclonal anti-mouse EPO antibody
fluorescence detector (Wallac). (Santa Cruz Biotechnology), followed by immunoblot with a monoclonal
antibody (Pharmingen). Relative levels were determined by densitometry.
HIF-1/p300 immunoprecipitation For blood counts, blood was collected in anticoagulant, and complete blood
Hep3B cells were treated with 50 nM chetomin or DMSO for 2 hr prior to counts were performed by the clinical laboratory. For Glut1 and VEGF deter-
addition of 125 
M DFO. After 18 hr, cells were scraped into ice-cold PBS, mination, tumors were excised, and half of each tumor was fixed in buffered
and nuclear extracts were prepared using the NE-PER kit (Pierce) according 10% formalin and then immunostained for Glut1 as previously described
to the manufacturer’s instructions. Standardized aliquots of 10 mg of nuclear (Kondo et al., 2002). The other half of each tumor was flash frozen in liquid
extract were incubated with 2 
g each of OZ12 and OZ15 (Arany et al., 1996) nitrogen, pulverized to a powder with a mortar and pestle, and lysed in RIPA
HIF-1-specific monocolonal antibodies for 2 hr at 4C and immobilized on buffer (150 nM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, and 50 mM Tris
Protein A/G Sepharose (Amersham) for 1 hr. Beads were extensively washed [pH 7.4]) containing protease inhibitors (Complete, Roche). Standardized
with 50 mM Tris 8.0, 300 mM NaCl, 1% NP-40, 1 mM DTT, and protease aliquots of 0.1 mg of total protein were assayed using an ELISA specific for
inhibitors (EDTA-free Complete, Roche). Samples were fractionated on SDS- human VEGF (R&D Systems) according to the manufacturer’s instructions.
PAGE, transferred to nitrocellulose, and immunoblotted with p300-specific
(RW128) or HIF-1-specific (NB100; Novus) antibodies. In vivo imaging and xenografts
HepG2 cells (ATCC) were cotransfected with either EPO-luciferase (EPO-
In vitro interaction and cell-based reporter assays Luc) or CMV-luciferase along with a neomycin phosphotransferase expres-
In vitro pull-down, hypoxia reporter, and mammalian two-hybrid assays were sion vector. G418-resistent colonies were isolated and assayed for respon-
performed as previously described (Bhattacharya et al., 1999; Kung et al., siveness to hypoxia. A clone of HepG2 with stably integrated EPO-Luc was
2000). See the Supplemental Data at http://www.cancercell.org/cgi/content/ identified with 100-fold induction in cell culture. For validation, aliquots of
full/6/1/33/DC1 for further details. this clone were infected with pMMP, pMMP-dnHIF, pBP, or pBP-HIF-VP16
as described previously (Kung et al., 2000). Xenografts were generated by
NMR spectroscopy injecting 5  106 of the indicated cells subcutaneously in NCr/Nude mice
A complex of HIF-1/CH1 was prepared as previously described (Freedman (Taconic). Mice were anesthetized with a mixture of ketamine hydrochloride
et al., 2002). CH1 alone was produced in a similar way but was purified (150 mg/kg), xylazine (12 mg/kg), and D-luciferin (50 mg/ml) (Xenogen, Ala-
by cation exchange (HiTrap SP HP; Amersham) followed by gel filtration meda, CA) and imaged utilizing the In Vivo Imaging System (IVIS; Xenogen)
(Superdex75; Amersham). Samples were prepared by dissolving 125 
M for a duration of 60–120 s. Mice were allowed to recover under isothermic
unlabeled protein in 10 mM deuterated MES (pH 6.0), 90% D2O with or conditions after imaging. To quantify bioluminescence, identical standard-
without 100 mM NaCl, 0.1 mM ZnSO4, and 1 mM deuterated DTT. One- ized circular regions of interest (ROI) were positioned to encircle the areas
dimensional 1H NMR spectra were acquired on a Unity Inova 500 MHz of emission, and the integrated flux of photons through each ROI (photons/
spectrometer (Varian) at 25C. Data were processed using the program s) was determined using the Living Images software package (Xenogen).
PROSA, and the spectra were displayed using the program XEASY. Cheto- For in vivo two-hybrid interaction imaging, reporter cells were created
min (25 mM) in 100% DMSO was added to protein samples in aqueous by transfecting HCT116 cells with expression vectors encoding Gal4-TADC,
solution to final concentrations of 50 
M, 100 
M, and 250 
M. In control VP16-CH1, and Gal4-Luc, as described in the Supplemental Data at http://
experiments, DMSO alone was added to protein samples using volumes www.cancercell.org/cgi/content/full/6/1/33/DC1. Control cells were co-
that matched each of the chetomin additions (maximum 1% DMSO in each transfected with an expression vector encoding Gal4 DNA binding domain
sample). EDTA (1 mM) was added to a protein sample containing 1% DMSO directly fused with the VP16 transactivation domain (Gal4-VP16) along with
but not chetomin. Gal4-Luc. Four hours after transfection with Lipofectamine 2000 (Invitrogen),
107 control cells were injected subcutaneously into the left flank, and 107
two-hybrid reporter cells were injected into the right flank. Animals wereReal-time PCR
Hep3B cells were treated with compound or vehicle control for 8 hr prior to imaged as described 24 hr after implantation and then divided into cohorts
of mice which were treated with two doses of chetomin at 2 mg/kg or vehicleinduction of hypoxia. Cells were maintained in hypoxia overnight, washed to
remove debris, and total RNA was harvested using Trizol reagent (Invitrogen) control via tail vein injection (doses separated by 18 hr). Mice were reimaged
6 hr after the second dose (24 hr after first image). The flux of photons throughaccording to the manufacturer’s protocol. Reverse transcription was per-
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chin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998).standardized regions of interest was determined as described above. For
Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumoureach animal, changes in the two-hybrid reporter activity (right flank) were
angiogenesis. Nature 394, 485–490.normalized to changes in the control emission (left flank) to correct for
nonspecific changes in gene expression or luminescence, and results are Carrero, P., Okamoto, K., Coumailleau, P., O’Brien, S., Tanaka, H., and
expressed relative to the baseline ratio [Relative two-hybrid interaction  Poellinger, L. (2000). Redox-regulated recruitment of the transcriptional co-
(PostRxFlux2hybrid/BaselineFlux2hybrid)/(PostRxFluxcontrol/BaselineFluxcontrol)]. activators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1.
HCT116 and PC3 xenografts were generated by subcutaneous injection Mol. Cell. Biol. 20, 402–415.
of 5 106 cells into NCr/Nude mice. Where indicated, mice were purchased
Cochran, A.G. (2000). Antagonists of protein-protein interactions. Chem.with jugular central venous catheters (CVC) in place. After 1 week of growth,
Biol. 7, R85–R94.mice with measurable tumors were segregated into treatment groups of
six to eight animals with unilateral xenografts or five animals with bilateral Damert, A., Machein, M., Breier, G., Fujita, M.Q., Hanahan, D., Risau, W.,
xenografts. Where indicated, chetomin or vehicle control was administered and Plate, K.H. (1997). Up-regulation of vascular endothelial growth factor
via CVC for the useable lifespan of the CVC, at which time mice were dosed expression in a rat glioma is conferred by two distinct hypoxia-driven mecha-
via tail vein injections. Tumors were measured with calipers, and the tumor nisms. Cancer Res. 57, 3860–3864.
volume was calculated as 0.5  length  width2.
Darnell, J.E. (2002). Transcription factors as targets for cancer therapy. Nat.All animal procedures were performed under the auspices of protocols
Rev. Cancer 2, 740–749.
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